News | April 28, 2026
Aurigene bets big on CRDMO expansion with $100 million outlay
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
The first of four planned modules at the new plant is expected to come online by summer 2026
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The company also reported significant progress toward its internally defined Sustainable Development Goals
The inspection concluded with one minor observation in Form 483
The company will respond to the US FDA within the stipulated timelines
Subscribe To Our Newsletter & Stay Updated
